Study or Subgroup	Placebo/MTX Events	Total	JAKI+MTX Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
1.1.1 Tofacitinib 5mg + MTX						
Burmester 2013	0	33	0	83		Not estimable
Van der Hejide 2019	0	60	15	637	7.9%	0.34 [0.02, 5.57]
Vollenhaven 2012	0	32	2	239	6.8%	1.45 [0.07, 29.64]
Subtotal (95% CI)		**125**		**959**	**14.7%**	**0.66 [0.09, 5.18]**
Total events	0		17			
Heterogeneity: Tau² = 0.00; Chi² = 0.52, df = 1 (P = 0.47); I² = 0%						
Test for overall effect: Z = 0.39 (P = 0.70)						
1.1.2 Tofacitinib 10mg + MTX						
Burmester 2013	0	33	0	84		Not estimable
Van der Hejide 2019	0	60	12	649	7.8%	0.43 [0.03, 7.11]
Vollenhaven 2012	0	32	1	233	6.1%	2.36 [0.10, 56.83]
Subtotal (95% CI)		**125**		**966**	**14.0%**	**0.90 [0.11, 7.44]**
Total events	0		13			
Heterogeneity: Tau² = 0.00; Chi² = 0.67, df = 1 (P = 0.41); I² = 0%						
Test for overall effect: Z = 0.09 (P = 0.93)						
1.1.3 Upadacitinib 3mg + MTX						
Genovese 2016	0	12	0	12		Not estimable
Kremer 2016	0	13	0	13		Not estimable
Subtotal (95% CI)		**25**		**25**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.4 Upadacitinib 6mg + MTX						
Genovese 2016	0	12	1	12	6.4%	0.33 [0.01, 7.45]
Kremer 2016	0	13	1	13	6.4%	0.33 [0.01, 7.50]
Subtotal (95% CI)		**25**		**25**	**12.8%**	**0.33 [0.04, 3.01]**
Total events	0		2			
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%						
Test for overall effect: Z = 0.98 (P = 0.33)						
1.1.5 Upadacitinib 12mg + MTX						
Genovese 2016	0	12	0	12		Not estimable
Kremer 2016	0	13	0	13		Not estimable
Subtotal (95% CI)		**25**		**25**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.6 Upadacitinib 15mg + MTX						
Fleischman 2019	2	250	0	290	6.7%	5.80 [0.28, 120.18]
Subtotal (95% CI)		**250**		**290**	**6.7%**	**5.80 [0.28, 120.18]**
Total events	2		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.14 (P = 0.26)						
1.1.7 Upadacitinib 18mg + MTX						
Genovese 2016	0	12	0	12		Not estimable
Kremer 2016	0	13	0	13		Not estimable
Subtotal (95% CI)		**25**		**25**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.8 Upadacitinib 24mg + MTX						
Genovese 2016	0	12	0	11		Not estimable
Subtotal (95% CI)		**12**		**11**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.9 Baricitinib 1mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.10 Baricitinib 2mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.11 Baricitinib 4mg + MTX						
Fleischman 2017	1	210	4	215	13.0%	0.26 [0.03, 2.27]
Li 2020	0	57	0	62		Not estimable
Tanaka 2016	0	11	0	6		Not estimable
Taylor 2017	3	198	3	431	24.5%	2.18 [0.44, 10.69]
Subtotal (95% CI)		**476**		**714**	**37.5%**	**0.85 [0.10, 7.02]**
Total events	4		7			
Heterogeneity: Tau² = 1.40; Chi² = 2.48, df = 1 (P = 0.12); I² = 60%						
Test for overall effect: Z = 0.15 (P = 0.88)						
1.1.12 Baricitinib 8mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.13 Peficitinib 25mg + MTX						
Kivitz 2017	0	17	0	15		Not estimable
Subtotal (95% CI)		**17**		**15**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.14 Peficitinib 50mg + MTX						
Kivitz 2017	0	17	0	18		Not estimable
Subtotal (95% CI)		**17**		**18**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.15 Peficitinib 100mg + MTX						
Kivitz 2017	0	17	0	19		Not estimable
Takeuchi 2019	1	63	1	162	8.2%	2.57 [0.16, 40.49]
Subtotal (95% CI)		**80**		**181**	**8.2%**	**2.57 [0.16, 40.49]**
Total events	1		1			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.67 (P = 0.50)						
1.1.16 Peficitinib 150mg + MTX						
Kivitz 2017	0	17	0	18		Not estimable
Takeuchi 2019	1	63	0	163	6.1%	7.69 [0.32, 186.26]
Subtotal (95% CI)		**80**		**181**	**6.1%**	**7.69 [0.32, 186.26]**
Total events	1		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.25 (P = 0.21)						
1.1.17 Filgotinib 25mg + MTX						
Westhovens 2017	0	32	0	34		Not estimable
Subtotal (95% CI)		**32**		**34**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.18 Filgotinib 50mg + MTX						
Westhovens 2017	0	32	0	78		Not estimable
Subtotal (95% CI)		**32**		**78**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.19 Filgotinib 100mg + MTX						
Westhovens 2017	0	32	0	84		Not estimable
Subtotal (95% CI)		**32**		**84**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.1.20 Filgotinib 200mg + MTX						
Westhovens 2017	0	32	0	38		Not estimable
Subtotal (95% CI)		**32**		**38**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
Total (95% CI)		**1443**		**3687**	**100.0%**	**1.13 [0.51, 2.47]**
Total events	8		40			
Heterogeneity: Tau² = 0.00; Chi² = 7.96, df = 10 (P = 0.63); I² = 0%						
Test for overall effect: Z = 0.29 (P = 0.77)						
Test for subgroup differences: Chi² = 4.40, df = 6 (P = 0.62), I² = 0%